| http://www.w3.org/ns/prov#value | - acquisitions, divestitures, restructurings, product withdrawals and other unusual items, including Pfizer's ability to realize the projected benefits of its acquisition of Wyeth and of its cost-reduction initiatives.Forward-looking statements in this release should be evaluated together with other risks and uncertainties discussed in Pfizer's and King's filings with the U.S. Securities and Exchan
|
